Targeting and limiting surgery for patients with node-positive breast cancer

BMC Medicine

Henry M. Kuerer¹  Abigail S. Caudle¹ 

[1] Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit1484, Houston 77230-1402, TX, USA

关键词: Targeted axillary dissection;    Sentinel lymph node;    Nodal metastasis;    Neoadjuvant chemotherapy;    Breast cancer;    Axillary lymphadenectomy;   

Others  :  1216030
DOI  :  10.1186/s12916-015-0385-5

 received in 2015-04-14, accepted in 2015-06-03,  发布年份 2015

【 摘 要 】

The presence of axillary nodal metastases has a significant impact on locoregional and systemic treatment decisions. Historically, all node-positive patients underwent complete axillary lymph node dissection; however, this paradigm has changed over the last 10 years. The use of sentinel lymph node dissection has expanded from its initial role as a surgical staging procedure in clinically node-negative patients. Clinically node-negative patients with small volume disease found on sentinel lymph node dissection now commonly avoid more extensive axillary surgery. There is interest in expanding this role to node-positive patients who receive neoadjuvant chemotherapy as a way to restage the axilla in hopes of sparing women who convert to node-negative status from the morbidity of complete nodal clearance. While sentinel lymph node dissection alone may not accomplish this goal, there are novel techniques, such as targeted axillary dissection, that may now allow for reliable nodal staging after chemotherapy.

【 授权许可】

   
2015 Caudle and Kuerer.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Carter C, Allen C, Henson D. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63:181-7.
• [2]Beenken S, Urist M, Zhang Y, Desmond R, Krontiras H, Medina H et al.. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg. 2003; 237:732-8.
• [3]AJCC Cancer Staging Manual. 7th edn. New York: Springer; 2009.
• [4]Giuliano A, Hunt K, Ballman K, Beitsch P, Whitworth P, Blumencranz P et al.. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305:569-75.
• [5]Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE et al.. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15:1303-10.
• [6]Galimberti V, Cole B, Zurrida S, Viale G, Luini A, Veronesi P et al.. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14:297-305.
• [7]Boughey J, Suman V, Mittendorf E, Ahrendt G, Wilke L, Taback B et al.. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013; 310:1455-61.
• [8]Boughey J, Ballman K, Hunt K, McCall L, Mittendorf E, Ahrendt G, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015. Ahead of print. Epub 2015 Feb 2.
• [9]Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausshild M, Helms G et al.. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013; 14:609-18.
• [10]Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L et al.. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study. J Clin Oncol. 2015; 33:258-64.
• [11]Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg V, Shriver C et al.. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998; 339:941-6.
• [12]National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Breast, version 2. 2008. http://www. nccn.org/professionals/physician_gls/f_guidelines.asp webcite
• [13]Caudle A, Hunt K, Tucker S, Hoffman K, Gainer S, Lucci A et al.. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012; 19:3144-51.
• [14]Giuliano A, McCall L, Beitsch P, Whitworth P, Blumencranz P, Leitch A et al.. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010; 252:426-32.
• [15]Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA et al.. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014; 32:3600-6.
• [16]Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al.. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17:460-9.
• [17]Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al.. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384:164-72.
• [18]Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf E, Le-Petross H et al.. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010; 116:2884-9.
• [19]Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese R et al.. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15:2479-82.
• [20]Kuerer H, Sahin A, Hunt K, Newman L, Breslin T, Ames F et al.. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999; 230:72-8.
• [21]Jones J, Zabicki K, Christian R, Gadd M, Hughes K, Lesnokoski B et al.. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg. 2005; 190:517-20.
• [22]Rouzier R, Extra J, Klijanienko J, Falcou M, Asselain B, Vincent-Salomon A et al.. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002; 20:1304-10.
• [23]Hunt K, Yi M, Mittendorf E, Guerrero C, Babiera G, Bedrosian I et al.. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009; 250:558-66.
• [24]Boughey J, McCall L, Ballman K, Mittendorf E, Ahrendt G, Wilke L et al.. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014; 260:608-14.
• [25]Buzdar A, Ibrahim N, Francis D, Booser D, Thomas E, Theriault R et al.. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23:3676-84.
• [26]Shen J, Gilcrease M, Babiera G, Ross M, Meric-Bernstam F, Feig B et al.. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007; 109:1255-63.
• [27]Gimbergues P, Abrial C, Durando X, Le Bouedec G, Cachin F, Penault-Llorca F et al.. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008; 15:1316-21.
• [28]Classe J, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J et al.. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009; 27:726-32.
• [29]Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf E, Bedrosian I et al.. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012; 19:3177-84.
• [30]Boughey J, Suman V, Mittendorf E, Ahrendt G, Wilke L, Taback B et al.. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015; 261:547-52.
• [31]Kang T, Yi M, Hunt K, Mittendorf E, Babiera G, Kuerer H et al.. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010; 17:S280-5.
• [32]Morrow M, Rademaker A, Bethke K, Talamonti M, Dawes L, Clauson J et al.. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery. 1999; 126:714-20.
• [33]Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy – Results from a prospective trial – ACOSOG Z1071 (Alliance). http://eposter. abstractsonline.com/sabcs webcite
• [34]Caudle A, Yang W, Mittendorf E, Black D, Gilcrease M, Bedrosian I et al.. Targeted axillary dissection improves axillary evaluation following neoadjuvant chemotherapy in node positive patients. Society of Surgical Oncology, Annual Cancer Meeting, Houston, TX; 2015.
• [35]Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA et al.. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI Procedure. Ann Surg. 2015; 261:378-82.
• [36]Caudle A, Yang W, Mittendorf E, Black D, Hwang R, Hobbs B et al.. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015; 150:137-43.
• [37]Dauer L, Thornton C, Miodownik D, Boylan D, Holahan B, Kin V et al.. Radioactive seed localization with 125I for nonpalpable lesions prior to breast lumpectomy and/or excisional biopsy: methodology, safety, and experience of initial year. Health Phys. 2013; 105:356-65.
• [38]Jakub J, Gray R, Degnim A, Boughey J, Gardner M, Cox C. Current status of radioactive seed for localization of non-palpable breast lesions. Am J Surg. 2010; 199:522-8.
• [39]Choy N, Lipson J, Porter C, Ozawa M, Kieryn A, Pal S et al.. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol. 2015; 22:377-82.
• [40]A Randomized Phase III Clinical Trial Evaluation Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. NSABP-51/RTOG 1304 Trial, NCT01872975.
• [41]Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. Alliance A11202 Trial, NCT01872975.